Structural and Compound ALK Resistance Mutations: A Unified Framework to Understand Lorlatinib Failure and Beyond
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have dramatically transformed the clinical management of ALK-rearranged non-small cell lung cancer (NSCLC). Successive generations of ALK inhibitors have been developed to overcome resistance mediated by kinase domain mutations, culm...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI AG
2026-06-01
|
| coleção: | Journal of Respiration |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/2673-527X/6/2/11 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|